Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 7Thoracic 1Head & Neck 1Genitourinary 1Dermatologic 1Breast 1

Conditions

Breast Neoplasms 2767Triple Negative Breast Neoplasms 406Neoplasm Metastasis 156Breast Neoplasms, Male 102Neoplasms 100Ovarian Neoplasms 69Carcinoma, Non-Small-Cell Lung 68Carcinoma, Intraductal, Noninfiltrating 68Lung Neoplasms 66Brain Neoplasms 60Colorectal Neoplasms 52Inflammatory Breast Neoplasms 50Advanced Breast Cancer 48Breast Carcinoma In Situ 47Prostatic Neoplasms 42Melanoma 38Pancreatic Neoplasms 37Stomach Neoplasms 32Uterine Cervical Neoplasms 28Sarcoma 27HER2-positive Breast Cancer 27Endometrial Neoplasms 25Head and Neck Neoplasms 24Recurrence 23Colonic Neoplasms 22Carcinoma, Renal Cell 21Carcinoma, Ovarian Epithelial 21Small Cell Lung Carcinoma 20Multiple Myeloma 20Carcinoma, Ductal, Breast 20

Interventions

spartalizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Spinocerebellar Degenerations × Breast × Clear all
NCT03207867 2024-10-09

A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma

Novartis

Phase 2 Terminated
315 enrolled 73 charts
BreastDermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Pancreatic Neoplasms, Spinocerebellar Degenerations, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡